135 related articles for article (PubMed ID: 19729426)
1. Biomarkers for lupus nephritis: the quest continues.
Rovin BH; Zhang X
Clin J Am Soc Nephrol; 2009 Nov; 4(11):1858-65. PubMed ID: 19729426
[TBL] [Abstract][Full Text] [Related]
2. The role of cytokines as biomarkers in systemic lupus erythematosus and lupus nephritis.
Adhya Z; Borozdenkova S; Karim MY
Nephrol Dial Transplant; 2011 Oct; 26(10):3273-80. PubMed ID: 21372259
[TBL] [Abstract][Full Text] [Related]
3. Biomarker discovery in human SLE nephritis.
Rovin BH; Birmingham DJ; Nagaraja HN; Yu CY; Hebert LA
Bull NYU Hosp Jt Dis; 2007; 65(3):187-93. PubMed ID: 17922668
[TBL] [Abstract][Full Text] [Related]
4. Anti-C1q antibodies in nephritis: correlation between titres and renal disease activity and positive predictive value in systemic lupus erythematosus.
Marto N; Bertolaccini ML; Calabuig E; Hughes GR; Khamashta MA
Ann Rheum Dis; 2005 Mar; 64(3):444-8. PubMed ID: 15286009
[TBL] [Abstract][Full Text] [Related]
5. CXCR3+CD4+ T cells are enriched in inflamed kidneys and urine and provide a new biomarker for acute nephritis flares in systemic lupus erythematosus patients.
Enghard P; Humrich JY; Rudolph B; Rosenberger S; Biesen R; Kuhn A; Manz R; Hiepe F; Radbruch A; Burmester GR; Riemekasten G
Arthritis Rheum; 2009 Jan; 60(1):199-206. PubMed ID: 19116922
[TBL] [Abstract][Full Text] [Related]
6. Anti-C1q autoantibodies in lupus nephritis: prevalence and clinical significance.
Sinico RA; Radice A; Ikehata M; Giammarresi G; Corace C; Arrigo G; Bollini B; Li Vecchi M
Ann N Y Acad Sci; 2005 Jun; 1050():193-200. PubMed ID: 16014534
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic value of anti-nucleosome antibodies in the assessment of disease activity of systemic lupus erythematosus: a prospective study comparing anti-nucleosome with anti-dsDNA antibodies.
Gutiérrez-Adrianzén OA; Koutouzov S; Mota RM; das Chagas Medeiros MM; Bach JF; de Holanda Campos H
J Rheumatol; 2006 Aug; 33(8):1538-44. PubMed ID: 16783863
[TBL] [Abstract][Full Text] [Related]
8. Clinical, biochemical and pathological predictors of poor response to intravenous cyclophosphamide in patients with proliferative lupus nephritis.
Conlon PJ; Fischer CA; Levesque MC; Smith SR; St Clair EW; Allen NB; Fleming JA; Howell DN
Clin Nephrol; 1996 Sep; 46(3):170-5. PubMed ID: 8879851
[TBL] [Abstract][Full Text] [Related]
9. Anti-C1q antibodies and antiendothelial cell antibodies in systemic lupus erythematosus - relationship with disease activity and renal involvement.
Oelzner P; Deliyska B; Fünfstück R; Hein G; Herrmann D; Stein G
Clin Rheumatol; 2003 Oct; 22(4-5):271-8. PubMed ID: 14576989
[TBL] [Abstract][Full Text] [Related]
10. Comparative value of urinalysis, urine cytology and urine sIL2R in the assessment of renal disease in patients with systemic lupus erythematosus (SLE).
Roberti I; Dikman S; Spiera H; Reisman L; Eichenfield AH; Lieberman KV
Clin Nephrol; 1996 Sep; 46(3):176-82. PubMed ID: 8879852
[TBL] [Abstract][Full Text] [Related]
11. High prevalence of anti-C1q antibodies in biopsy-proven active lupus nephritis.
Trendelenburg M; Lopez-Trascasa M; Potlukova E; Moll S; Regenass S; Frémeaux-Bacchi V; Martinez-Ara J; Jancova E; Picazo ML; Honsova E; Tesar V; Sadallah S; Schifferli J
Nephrol Dial Transplant; 2006 Nov; 21(11):3115-21. PubMed ID: 16877491
[TBL] [Abstract][Full Text] [Related]
12. Biomarkers for systemic lupus erythematosus.
Ahearn JM; Liu CC; Kao AH; Manzi S
Transl Res; 2012 Apr; 159(4):326-42. PubMed ID: 22424435
[TBL] [Abstract][Full Text] [Related]
13. Urinary TWEAK and the activity of lupus nephritis.
Schwartz N; Su L; Burkly LC; Mackay M; Aranow C; Kollaros M; Michaelson JS; Rovin B; Putterman C
J Autoimmun; 2006 Dec; 27(4):242-50. PubMed ID: 17257812
[TBL] [Abstract][Full Text] [Related]
14. Biomarkers in lupus nephritis.
Manoharan A; Madaio MP
Rheum Dis Clin North Am; 2010 Feb; 36(1):131-43, ix. PubMed ID: 20202595
[TBL] [Abstract][Full Text] [Related]
15. The prognosis of biopsy-proven lupus nephritis in chinese patients: long term follow-up of 86 cases.
Shen K; Yu Y; Tang Z; Liu Z; Li L
Chin Med J (Engl); 1997 Jul; 110(7):502-7. PubMed ID: 9594205
[TBL] [Abstract][Full Text] [Related]
16. Urine osteoprotegerin and monocyte chemoattractant protein-1 in lupus nephritis.
Kiani AN; Johnson K; Chen C; Diehl E; Hu H; Vasudevan G; Singh S; Magder LS; Knechtle SJ; Petri M
J Rheumatol; 2009 Oct; 36(10):2224-30. PubMed ID: 19648301
[TBL] [Abstract][Full Text] [Related]
17. Adrenomedullin--a potential disease activity marker and suppressor of nephritis activity in systemic lupus erythematosus.
Mak A; Cheung BM; Mok CC; Leung R; Lau CS
Rheumatology (Oxford); 2006 Oct; 45(10):1266-72. PubMed ID: 16595522
[TBL] [Abstract][Full Text] [Related]
18. Hepatocyte growth factor and transforming growth factor beta1 ratio at baseline can predict early response to cyclophosphamide in systemic lupus erythematosus nephritis.
Capuano A; Costanzi S; Peluso G; Zannoni G; Vellone VG; Gremese E; Zoli A; Scott C; Beltrami CA; Romano G; Ferraccioli G
Arthritis Rheum; 2006 Nov; 54(11):3633-9. PubMed ID: 17075808
[TBL] [Abstract][Full Text] [Related]
19. Urinary proteomic profiles distinguish between active and inactive lupus nephritis.
Mosley K; Tam FW; Edwards RJ; Crozier J; Pusey CD; Lightstone L
Rheumatology (Oxford); 2006 Dec; 45(12):1497-504. PubMed ID: 17046860
[TBL] [Abstract][Full Text] [Related]
20. Potential for glomerular C4d as an indicator of thrombotic microangiopathy in lupus nephritis.
Cohen D; Koopmans M; Kremer Hovinga IC; Berger SP; Roos van Groningen M; Steup-Beekman GM; de Heer E; Bruijn JA; Bajema IM
Arthritis Rheum; 2008 Aug; 58(8):2460-9. PubMed ID: 18668574
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
